AVANOS MEDICAL Business Summary

Avanos Medical, Inc. (AVNS) is a specialized medical technology firm that generates revenue through the development and global distribution of proprietary medical devices, primarily utilizing a high-volume consumable sales model. The company’s operations are divided into two primary segments: Specialty Nutrition Systems (SNS) and Pain Management and Recovery (PMR). The SNS portfolio includes market-leading enteral feeding tubes and neonatal solutions under brands like MIC-KEY and NeoMed, while the PMR segment focuses on non-opioid pain therapies such as COOLIEF radiofrequency ablation and ON-Q surgical infusion pumps. Following its 2025 strategic divestiture of lower-margin assets and the acquisition of Nexus Medical, Avanos has solidified its position as a niche leader in chronic care and acute pain management. It competes against major diversified players like Medtronic, Boston Scientific, and Teleflex, as well as specialty competitors like Pacira BioSciences, distinguishing itself through a concentrated focus on non-opioid clinical outcomes. The executive leadership is headed by CEO David Pacitti, who assumed the role in April 2025 following a distinguished tenure as Head of the Americas at Siemens Healthineers. He is joined by CFO Scott Galovan, a veteran strategist with over a decade at the company and prior experience at Intel Capital and Newell Brands. Originally established via a 2014 spin-off from Kimberly-Clark (formerly Halyard Health), the company’s governance is led by Chairman Gary Blackford and a board that includes recent January 2026 appointee Maria Sainz, a veteran med-tech executive with over 30 years of industry experience. This team is currently spearheading a multi-year transformation strategy focused on reaching $1 billion in revenue by 2030 through portfolio optimization, operational efficiency, and the mitigation of global supply chain and tariff pressures.